Patients (N = 100) | ||
---|---|---|
Characteristics | No. | |
Age, years | ||
Median | 69 | |
Range | 51-92 | |
ECOG performance status | ||
0 | 91 | |
1 | 9 | |
HLA typing | ||
A24 | 66 | |
A2 | 21 | |
A3 supertype | 11 | |
A26 | 2 | |
Baseline PSA, ng/ml | ||
Median | 29.8 | |
Range | 0.2-2481 | |
PSADT, months | ||
Median | 2 | |
Range | 0.3-36+ | |
Lymphocyte, 1300/μL | ||
Low | 41 | |
High | 59 | |
CRP, 3 μg/mL | ||
Low | 53 | |
High | 47 | |
SAA, 8 μg/mL | ||
Low | 27 | |
High | 76 | |
IL6, 2.4 pg/mL | ||
Low | 84 | |
High | 16 | |
Gleason score | ||
≤7 | 34 | |
≥8 | 57 | |
Unknown | 9 | |
Site of metastasis | ||
no | 14 | |
Bone only | 33 | |
Bone and nodal/organ | 40 | |
Nodal/organ | 13 | |
Prior chemotherapy | ||
(-) | 60 | |
(+) | 40 |